These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34253595)

  • 1. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
    Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y
    Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia.
    Ramsey HE; Greenwood D; Zhang S; Childress M; Arrate MP; Gorska AE; Fuller L; Zhao Y; Stengel K; Fischer MA; Stubbs MC; Liu PCC; Boyd K; Rathmell JC; Hiebert SW; Savona MR
    Clin Cancer Res; 2021 Jan; 27(2):598-607. PubMed ID: 33148670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
    Wang X; Mak PY; Mu H; Tao W; Rao A; Visweswaran R; Ruvolo V; Pachter JA; Weaver DT; Andreeff M; Xu B; Carter BZ
    Mol Cancer Ther; 2020 Aug; 19(8):1636-1648. PubMed ID: 32404407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Moujalled DM; Pomilio G; Ghiurau C; Ivey A; Salmon J; Rijal S; Macraild S; Zhang L; Teh TC; Tiong IS; Lan P; Chanrion M; Claperon A; Rocchetti F; Zichi A; Kraus-Berthier L; Wang Y; Halilovic E; Morris E; Colland F; Segal D; Huang D; Roberts AW; Maragno AL; Lessene G; Geneste O; Wei AH
    Leukemia; 2019 Apr; 33(4):905-917. PubMed ID: 30214012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
    Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN
    Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models.
    Garg R; Allen KJH; Dawicki W; Geoghegan EM; Ludwig DL; Dadachova E
    Cancer Med; 2021 Feb; 10(3):1128-1140. PubMed ID: 33347715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors.
    Lam LT; Lin X; Faivre EJ; Yang Z; Huang X; Wilcox DM; Bellin RJ; Jin S; Tahir SK; Mitten M; Magoc T; Bhathena A; Kati WM; Albert DH; Shen Y; Uziel T
    Mol Cancer Ther; 2017 Aug; 16(8):1511-1520. PubMed ID: 28468776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
    Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
    Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
    Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
    Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
    Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
    Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
    Nechiporuk T; Kurtz SE; Nikolova O; Liu T; Jones CL; D'Alessandro A; Culp-Hill R; d'Almeida A; Joshi SK; Rosenberg M; Tognon CE; Danilov AV; Druker BJ; Chang BH; McWeeney SK; Tyner JW
    Cancer Discov; 2019 Jul; 9(7):910-925. PubMed ID: 31048320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
    Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
    Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
    Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
    Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
    Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of
    Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
    J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
    Albert DH; Goodwin NC; Davies AM; Rowe J; Feuer G; Boyiadzis M; Dorritie KA; Mancini M; Gandour-Edwards R; Jonas BA; Borthakur G; Aldoss I; Rizzieri DA; Odenike O; Prebet T; Singh S; Popovic R; Shen YU; McDaniel KF; Kati WM; Modi DA; Motwani M; Wolff JE; Frost DJ
    In Vivo; 2022; 36(4):1615-1627. PubMed ID: 35738590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis targeted therapies in acute myeloid leukemia: an update.
    Ball S; Borthakur G
    Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.